Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks
receptor

FPRL1 (FPR2) and FPR3

also: FPRL1, FPR2, ALX, FPR2/ALX, FPR3, FPRL2, Formyl peptide receptor-like 1, lipoxin A4 receptor

Formyl peptide receptor-like 1 (FPRL1, now named FPR2/ALX) and the related receptor FPR3, G protein-coupled receptors reported to bind the mitochondria-derived peptide Humanin.

FPRL1 (formyl peptide receptor-like 1) is the earlier name of the receptor now called FPR2, also written FPR2/ALX. It is a seven-transmembrane G protein-coupled receptor in the formyl peptide receptor family. A 2009 nomenclature report from the International Union of Basic and Clinical Pharmacology (IUPHAR) lists three human members, FPR1, FPR2/ALX and FPR3. FPR3 (earlier called FPRL2) is a separate receptor, not another name for FPRL1, and the same report notes that fewer agonists have been identified for it than for the other two. FPRL1 and FPRL2 were cloned as genes with sequence homology to FPR1, and the bacterial peptide fMLF is inactive at FPR3. FPR2/ALX was first described as a low-affinity receptor for bacterial formylated peptides, and the anti-inflammatory lipid lipoxin A4 is an agonist at it, which is why "lipoxin A4 receptor" appears among its names.

Why it matters in peptide research

FPRL1/FPR2 sits between innate immune signalling and mitochondrial biology. In immune cells it is described as mediating chemotaxis, the movement of cells toward a chemical signal, and lipoxin A4 is reported to act through it as an anti-inflammatory signal. Its interest for peptide research comes from Humanin, a 24-amino-acid peptide encoded in mitochondrial DNA.

A 2004 study reported that synthetic Humanin attracted mononuclear phagocytes through human FPRL1 (and the mouse counterpart, FPR2), and that in neuroblast cells both Humanin and the amyloid-beta peptide Aβ42 activated FPRL1 while only Aβ42 caused cell death, which Humanin blocked. The authors suggested that Humanin might protect neurons by competing with Aβ42 for access to the receptor. A 2005 study in a mouse neuronal cell line found that silencing FPR2 did not remove Humanin's protective effect, and its authors suggested that another receptor also exists. A 2023 systematic review, which the Humanin page cites, describes a study in which Humanin's protection of neurons from amyloid-beta involved both FPRL1 and FPRL2 (FPR3) and depended on STAT signalling, and describes signalling through a CNTFR/gp130/WSX-1 complex that activates STAT3. FPRL1 may therefore account for only part of what Humanin does in cells. Whether FPRL1 mediates any effect of Humanin in people is not established.

Peptides studied in this context

  • Humanin — a 24-amino-acid mitochondria-encoded peptide. Its page describes the cell and mouse findings, including a 2020 mouse study in which systemic Humanin accelerated the growth of triple-negative breast tumours and lung metastases.

Common misconceptions

The Humanin findings do not make FPRL1 or FPR3 a settled mitochondrial peptide sensor: they are cell-culture reports, and the receptor-knockdown study above shows they are not settled. Results for one formyl peptide receptor should not be read across to another.

Published: 2026-05-16Last updated: 2026-11-06
  • Correction (2026-11-06): Corrected 6 November 2026 after a citation audit: FPRL1 was described as reclassified as FPR3, but the 2009 IUPHAR report names it FPR2/ALX and lists FPR3 as a separate receptor. Unsourced signalling, expression and potency claims were removed and 2004 and 2005 cell studies added.

If you spot an error or have new evidence to suggest, please use our corrections policy.

Related glossary entries

Continue reading